Recent QLGN News
- Lifecore Biomedical Announces Cooperation Agreement with 22NW • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:00:18 PM
- Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination • GlobeNewswire Inc. • 05/30/2024 08:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/14/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/04/2024 12:59:19 AM
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:30:40 PM
- Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 07:16:19 PM
- Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer • GlobeNewswire Inc. • 10/23/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 12:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:15:36 PM
- Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 • GlobeNewswire Inc. • 09/27/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:18 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:15:06 PM
- Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 08/17/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 02:04:16 PM
- Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 • GlobeNewswire Inc. • 08/15/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:16:09 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM